A Multi-Center, Open-Label, Phase I, Dose-Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2011
At a glance
- Drugs PTI 188 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 03 Feb 2011 Survival results will be presented at the 2011 American Society of Clinical Oncology Meeting, according to a Pain Therapeutics media release.
- 31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Mar 2010 Positive efficacy results evaluating both phase I trials in patients with metastatic melanoma in Israel have been reported in a Pain Therapeutics media release.